JP2012528155A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528155A5
JP2012528155A5 JP2012513053A JP2012513053A JP2012528155A5 JP 2012528155 A5 JP2012528155 A5 JP 2012528155A5 JP 2012513053 A JP2012513053 A JP 2012513053A JP 2012513053 A JP2012513053 A JP 2012513053A JP 2012528155 A5 JP2012528155 A5 JP 2012528155A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
poly
attached
pyridine ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012513053A
Other languages
English (en)
Japanese (ja)
Other versions
JP6297776B2 (ja
JP2012528155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/001561 external-priority patent/WO2010138194A2/en
Publication of JP2012528155A publication Critical patent/JP2012528155A/ja
Publication of JP2012528155A5 publication Critical patent/JP2012528155A5/ja
Application granted granted Critical
Publication of JP6297776B2 publication Critical patent/JP6297776B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012513053A 2009-05-27 2010-05-26 免疫調節薬−高分子化合物 Expired - Fee Related JP6297776B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US21711709P 2009-05-27 2009-05-27
US21711609P 2009-05-27 2009-05-27
US21712409P 2009-05-27 2009-05-27
US21712909P 2009-05-27 2009-05-27
US61/217,117 2009-05-27
US61/217,116 2009-05-27
US61/217,124 2009-05-27
US61/217,129 2009-05-27
PCT/US2010/001561 WO2010138194A2 (en) 2009-05-27 2010-05-26 Immunomodulatory agent-polymeric compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015219625A Division JP2016094411A (ja) 2009-05-27 2015-11-09 免疫調節薬−高分子化合物

Publications (3)

Publication Number Publication Date
JP2012528155A JP2012528155A (ja) 2012-11-12
JP2012528155A5 true JP2012528155A5 (cg-RX-API-DMAC7.html) 2018-02-08
JP6297776B2 JP6297776B2 (ja) 2018-03-20

Family

ID=43012672

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2012513052A Expired - Fee Related JP6297775B2 (ja) 2009-05-27 2010-05-26 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア
JP2012513051A Expired - Fee Related JP6282395B2 (ja) 2009-05-27 2010-05-26 異なる放出速度の構成要素を有するナノキャリア
JP2012513053A Expired - Fee Related JP6297776B2 (ja) 2009-05-27 2010-05-26 免疫調節薬−高分子化合物
JP2015197067A Pending JP2016041708A (ja) 2009-05-27 2015-10-02 異なる放出速度の構成要素を有するナノキャリア
JP2015204808A Expired - Fee Related JP6236048B2 (ja) 2009-05-27 2015-10-16 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア
JP2015219625A Pending JP2016094411A (ja) 2009-05-27 2015-11-09 免疫調節薬−高分子化合物
JP2017104002A Pending JP2017200925A (ja) 2009-05-27 2017-05-25 異なる放出速度の構成要素を有するナノキャリア
JP2017207967A Pending JP2018065808A (ja) 2009-05-27 2017-10-27 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012513052A Expired - Fee Related JP6297775B2 (ja) 2009-05-27 2010-05-26 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア
JP2012513051A Expired - Fee Related JP6282395B2 (ja) 2009-05-27 2010-05-26 異なる放出速度の構成要素を有するナノキャリア

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015197067A Pending JP2016041708A (ja) 2009-05-27 2015-10-02 異なる放出速度の構成要素を有するナノキャリア
JP2015204808A Expired - Fee Related JP6236048B2 (ja) 2009-05-27 2015-10-16 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア
JP2015219625A Pending JP2016094411A (ja) 2009-05-27 2015-11-09 免疫調節薬−高分子化合物
JP2017104002A Pending JP2017200925A (ja) 2009-05-27 2017-05-25 異なる放出速度の構成要素を有するナノキャリア
JP2017207967A Pending JP2018065808A (ja) 2009-05-27 2017-10-27 免疫調節薬のpH感応性放出がある標的指向性合成ナノキャリア

Country Status (12)

Country Link
US (9) US20110020388A1 (cg-RX-API-DMAC7.html)
EP (3) EP2435095A2 (cg-RX-API-DMAC7.html)
JP (8) JP6297775B2 (cg-RX-API-DMAC7.html)
KR (6) KR101916875B1 (cg-RX-API-DMAC7.html)
CN (7) CN107033339A (cg-RX-API-DMAC7.html)
AU (6) AU2010254549B2 (cg-RX-API-DMAC7.html)
BR (3) BRPI1012036A2 (cg-RX-API-DMAC7.html)
CA (3) CA2762650A1 (cg-RX-API-DMAC7.html)
EA (6) EA030246B1 (cg-RX-API-DMAC7.html)
IL (3) IL216548B (cg-RX-API-DMAC7.html)
MX (5) MX2011012598A (cg-RX-API-DMAC7.html)
WO (3) WO2010138192A2 (cg-RX-API-DMAC7.html)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US6993506B2 (en) 2000-12-05 2006-01-31 Jgr Acquisition, Inc. Method and device utilizing polymorphic data in e-commerce
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
ES2915692T3 (es) 2008-08-13 2022-06-24 California Inst Of Techn Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN102333538B (zh) * 2008-12-09 2014-01-15 科勒制药集团有限公司 免疫刺激性寡核苷酸
EP3067064B1 (en) 2008-12-09 2020-05-13 Novavax, Inc. Modified rsv f proteins and methods of their use
WO2010123569A2 (en) * 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
AU2010254549B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
MX343908B (es) * 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
CN105194665A (zh) 2010-05-26 2015-12-30 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP5909745B2 (ja) 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬
EP2648756A4 (en) * 2010-12-10 2016-06-08 California Inst Of Techn ATTAINING THE MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER
EP2495567A1 (en) * 2011-03-04 2012-09-05 Erasmus University Medical Center Rotterdam Methods and means for monitoring disruption of tissue homeostasis in the total body
EP2694040A4 (en) * 2011-03-25 2014-09-03 Selecta Biosciences Inc SYNTHETIC NANOTRACKERS WITH OSMOTICALLY MEDIATED RELEASE
ES2647902T3 (es) 2011-04-18 2017-12-27 University Of Georgia Research Foundation, Inc. Método de administración de vacunas
CN118078979A (zh) 2011-04-29 2024-05-28 西莱克塔生物科技公司 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
BR112014032207B1 (pt) 2012-06-21 2021-07-27 Northwestern University Composição compreendendo um antígeno acoplado a uma partícula transportadora e uso de um antígeno acoplado a uma partícula transportadora
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2968584A1 (en) 2013-03-11 2016-01-20 Cristal Delivery B.V. Vaccination composition
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10434088B2 (en) * 2013-05-03 2019-10-08 Selecta Biosciences, Inc. Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
CA2910579C (en) * 2013-05-03 2023-09-26 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
DK3003306T3 (da) * 2013-06-04 2020-11-30 Selecta Biosciences Inc Gentagen indgivelse af ikke-immunosupressive antigenspecifikke immunterapeutika
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
EP3033102B2 (en) 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
DE102013015112B4 (de) 2013-09-13 2016-07-14 Holger Frey Spaltbare Polyethylenglykol-(PEG)-Makromoleküle zum Einschluss von (Glyko-) Proteinen/Antigenen/Allergenen in abbaubaren Polyethylenglykol-(PEG)-Nanopartikeln sowie Verfahren zu ihrer Herstellung
US9603944B2 (en) 2013-09-27 2017-03-28 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
EP3071696B1 (en) 2013-11-22 2019-08-07 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US9919058B2 (en) 2014-07-15 2018-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US20170348402A1 (en) * 2014-07-30 2017-12-07 The Research Foundation For The State University Of New York System and method for delivering genetic material or protein to cells
WO2016037165A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
JP6887685B2 (ja) 2015-08-12 2021-06-16 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子の細胞表面共役
AU2016315478B2 (en) 2015-09-03 2023-07-13 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
EP3347047A1 (en) * 2015-09-09 2018-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
WO2017086794A1 (en) 2015-11-20 2017-05-26 Cristal Delivery B.V. Nanoparticles with active targeting
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
KR20180114946A (ko) * 2016-03-02 2018-10-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 sting 활성화 나노백신
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11433123B2 (en) 2016-07-21 2022-09-06 Case Western Reserve University Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
EP3568162A1 (en) 2017-01-10 2019-11-20 Nektar Therapeutics Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
ES3028362T3 (en) 2017-07-24 2025-06-19 Novavax Inc Methods and compositions for treating respiratory disease
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
WO2019222545A1 (en) 2018-05-16 2019-11-21 Synthego Corporation Methods and systems for guide rna design and use
TWI807036B (zh) * 2018-05-30 2023-07-01 南韓商韓國億諾生物有限公司 用於預防或治療癌症之包含作為活性成分之cd300e抑制劑的藥學組成物
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
SG11202105835YA (en) * 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
WO2020141225A1 (en) * 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
GB2597377A (en) 2019-01-25 2022-01-26 Synthego Corp Systems and methods for modulating CRISPR activity
US20220211740A1 (en) 2019-04-12 2022-07-07 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
GB2603223A (en) 2019-07-19 2022-08-03 Synthego Corp Stabilized Crispr complexes
CN111249453B (zh) * 2020-02-26 2021-11-19 浙江大学 一种纳米疫苗及其制备方法
WO2021231702A1 (en) * 2020-05-15 2021-11-18 Rutgers, The State University Of New Jersey Compositions and methods for treating wounds
EP4175618A4 (en) * 2020-07-01 2024-08-07 Cello Therapeutics, Inc. Platelet membrane coated nanoparticles and uses thereof
IL315371A (en) * 2020-08-31 2024-11-01 Rav Bariach 08 Industries Ltd Multi-bolt electromechanical locking system for remote operation
US11952492B2 (en) * 2020-11-20 2024-04-09 Encapsys, Llc Biodegradable, controlled release microcapsules
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
CN112494460B (zh) * 2020-12-10 2022-03-11 浙江大飞龙动物保健品股份有限公司 替米考星粉剂及其制备方法
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2023024500A1 (en) 2021-08-27 2023-03-02 Peking University Constructs and methods for preparing circular rna
CA3223230A1 (en) * 2021-09-17 2023-03-23 Jessica WALSH Reagent compositions, methods, cartridges, and systems
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
JP2025508467A (ja) 2022-02-24 2025-03-26 アイオー バイオテック エーピーエス 癌治療のヌクレオチド送達
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
KR20240076105A (ko) * 2022-11-23 2024-05-30 주식회사 바임 생분해성 고분자 분산체 및 이의 제조방법
TW202440929A (zh) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 用於感染性疾病的組合物和方法
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024196783A1 (en) * 2023-03-21 2024-09-26 The Board Of Regents Of The University Of Texas System Bioengineered colon-specific immune niche for the treatment of ulcerative colitis
CN117224699B (zh) * 2023-09-05 2024-03-19 贵州大学 一种纳米复合物及其制备方法和用途
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
CN119505213B (zh) * 2024-11-25 2025-12-09 吉林大学 一种聚碳酸酯聚合物及其制备方法、纳米佐剂和疫苗
CN119823126A (zh) * 2025-01-09 2025-04-15 沈阳药科大学 一种雷西莫特没食子酰基衍生物及其合成方法和应用

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7461M (cg-RX-API-DMAC7.html) 1968-06-19 1970-01-05
GB1355961A (en) * 1970-02-27 1974-06-12 Wellcome Found Preparation of immunosuppressive antilymphocytic serum
CH594444A5 (cg-RX-API-DMAC7.html) 1972-12-04 1978-01-13 Gerd Birrenbach
DK143689C (da) 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5912017A (en) 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
GB9016885D0 (en) 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
NZ242220A (en) 1991-04-02 1994-04-27 Biotech Australia Pty Ltd Complex for oral delivery of a substance to the circulatory or lymphatic drainage system comprising microparticle coupled to at least one carrier, the substance being encapsulated by the microparticle
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
JPH07509467A (ja) 1992-07-21 1995-10-19 ザ ゼネラル ホスピタル コーポレーション リンパ組織への薬物輸送システム
GB9216082D0 (en) 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
AU4932493A (en) 1992-09-25 1994-04-26 Dynagen, Inc. An immunobooster for delayed release of immunogen
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
DE69411154T2 (de) * 1993-02-22 1998-10-22 Alza Corp., Palo Alto, Calif. Mittel zur oralen gabe von wirkstoffen
WO1994021240A2 (de) 1993-03-17 1994-09-29 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995003035A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
WO1995022963A1 (en) 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
EP0938315B9 (en) 1996-10-25 2008-02-20 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
DE19745950A1 (de) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
DE69817393T2 (de) * 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
DE19827164A1 (de) 1998-06-18 1999-12-23 Merck Patent Gmbh Katalytisch Titan(IV)-oxid vermittelte geminale symmetrische Dialkylierung von Carbonsäureamiden
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
ATE321535T1 (de) 1998-07-29 2006-04-15 Chiron Corp Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
DE19839214C1 (de) * 1998-08-28 2000-05-25 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von sphärischen Mikropartikeln mit glatter Oberfläche, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid bestehen, sowie mit diesem Verfahren erhältliche Mikropartikel und deren Verwendung
US6306640B1 (en) 1998-10-05 2001-10-23 Genzyme Corporation Melanoma antigenic peptides
PL205109B1 (pl) 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6444192B1 (en) 1999-02-05 2002-09-03 The Regents Of The University Of California Diagnostic imaging of lymph structures
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6800296B1 (en) 1999-05-19 2004-10-05 Massachusetts Institute Of Technology Modification of surfaces using biological recognition events
US6815170B1 (en) 1999-06-30 2004-11-09 John Wayne Cancer Institute Methods for lymph node identification
WO2001012071A1 (en) 1999-08-13 2001-02-22 Point Biomedical Corporation Microparticles useful as ultrasonic contrast agents and for lymphatic system
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
EP1294930B1 (en) 2000-01-13 2011-03-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス, インコーポレイテッド ナノカプセルカプセル化システムおよび方法
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7192725B2 (en) 2000-05-19 2007-03-20 University Of Toronto Flagellin gene, flaC of Campylobacter
AU2001297913A1 (en) 2000-10-13 2002-12-23 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AU2002245205B2 (en) 2000-10-19 2007-07-19 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
NZ530315A (en) 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
JP4607452B2 (ja) 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20080233181A1 (en) 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
ATE394674T1 (de) 2002-04-22 2008-05-15 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
CA2487424C (en) 2002-05-30 2011-01-04 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US20040092470A1 (en) 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
US20040142887A1 (en) 2002-07-10 2004-07-22 Chengji Cui Antigen-polymer compositions
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US20060189554A1 (en) 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
US7008411B1 (en) * 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
NO20024755D0 (no) 2002-10-03 2002-10-03 Amersham Health As Metode
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
US20040156846A1 (en) 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
US8575110B2 (en) 2003-02-17 2013-11-05 Alpha-O Peptides G Peptidic nanoparticles as drug delivery and antigen display systems
US20040191215A1 (en) 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
US20060233883A1 (en) 2003-03-26 2006-10-19 Tsutomu Ishihara Intravenous nanoparticles for targeting drug delivery and sustained drug release
EP1605972A2 (en) * 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20060182793A1 (en) 2003-07-22 2006-08-17 Cytos Biotechnology Ag Cpg-packaged liposomes
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
US7829119B2 (en) 2003-10-20 2010-11-09 William Marsh Rice University Method to fabricate microcapsules from polymers and charged nanoparticles
EP1691780A2 (en) 2003-11-21 2006-08-23 Alza Corporation Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
WO2005055949A2 (en) 2003-12-09 2005-06-23 The Children's Hospital Of Philadelphia Sustained release preparations composed of biocompatible complex microparticles
KR20120105062A (ko) 2003-12-19 2012-09-24 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법
US20050191294A1 (en) 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US20070087986A1 (en) 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
EP2415481A3 (en) 2004-02-19 2012-04-18 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
US20060017339A1 (en) * 2004-06-03 2006-01-26 Lalit Chordia Brushless canned motor
DK1767216T3 (da) 2004-06-11 2012-09-03 Riken Lægemiddel med regulatorisk celleligand indeholdt i liposom
US7713550B2 (en) 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
WO2006014579A2 (en) 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
CN1692943A (zh) 2004-09-17 2005-11-09 四川大学 CpG DNA分子抗感染免疫制剂的制备和应用
GB0421296D0 (en) 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
EP1793863B1 (en) 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells
US20090004118A1 (en) * 2004-10-07 2009-01-01 Shuming Nie Multifunctional Nanoparticle Conjugates And Their Use
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
ES2434029T3 (es) 2004-11-15 2013-12-13 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
ATE544774T1 (de) 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc Rnai-modulation von mll-af4 und verwendungen dafür
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
CN101189339A (zh) 2005-03-22 2008-05-28 美得思达健康有限公司 诊断和治疗心血管疾病的递送系统和方法
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2006117217A2 (de) 2005-05-04 2006-11-09 Noxxon Pharma Ag Neue verwendung von spiegelmeren
EP1893661B1 (en) * 2005-05-10 2012-01-18 Emory University Strategies for delivery of active agents using micelles and particles
WO2006122127A1 (en) * 2005-05-10 2006-11-16 Naomi Balaban Compositions for administering rnaiii-inhibiting peptides
US9290617B2 (en) 2005-07-06 2016-03-22 Molly S. Shoichet Method of biomolecule immobilization on polymers using click-type chemistry
ES2556974T3 (es) 2005-08-12 2016-01-21 Jiang Liu Dispositivos para la orientación al sistema linfático
JP2009507049A (ja) * 2005-09-09 2009-02-19 北京徳科瑞医薬科技有限公司 リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
EP2883957A1 (en) 2005-11-25 2015-06-17 Zoetis Belgium S.A. Immunostimmulatory oligoribonucleotides
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
WO2007089870A2 (en) * 2006-01-31 2007-08-09 Medivas, Llc Vaccine delivery compositions and methods of use
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
CA2643322C (en) 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
CA2649149A1 (en) 2006-04-11 2007-10-25 Koko Kosmetikvertrieb Gmbh & Co. Kg Nanoparticle containing nicotine and/or cotinine, dispersions, and use thereof
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
EP2530086B1 (en) 2006-06-12 2019-03-20 Kuros Biosciences AG Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
JP2010502766A (ja) * 2006-06-16 2010-01-28 フロリダ アトランティック ユニヴァーシティ アジュバントとしてのキチン微粒子
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008019366A2 (en) 2006-08-07 2008-02-14 Ludwig Institute For Cancer Research Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
CN101500937A (zh) 2006-08-11 2009-08-05 万能药生物有限公司 用于递送活性成分的粒子及其制备方法和组合物
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
WO2008147456A2 (en) 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20080213377A1 (en) 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
WO2008071774A1 (en) 2006-12-14 2008-06-19 Cytos Biotechnology Ag Purification process for coat protein of rna bacteriophages
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
SI2510946T1 (sl) * 2007-02-07 2015-12-31 The Regents Of The University Of California Konjugati sintetičnih agonistov TLR in njihove uporabe
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008115641A2 (en) 2007-02-15 2008-09-25 Yale University Modular nanoparticles for adaptable vaccines
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
US11246831B2 (en) 2007-03-30 2022-02-15 Particle Sciences, Inc. Particle formulations and uses thereof
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2008124165A2 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
AU2008239795A1 (en) * 2007-04-12 2008-10-23 Emory University Novel strategies for delivery of active agents using micelles and particles
US8394914B2 (en) 2007-08-24 2013-03-12 Board Of Trustees Of Michigan State University Functional polyglycolide nanoparticles derived from unimolecular micelles
WO2009038685A1 (en) 2007-09-18 2009-03-26 The Scripps Research Institute Ligands for copper-catalyzed azide-alkyne cycloaddition reactions
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009052837A2 (en) * 2007-10-24 2009-04-30 Tallinn University Of Technology Maldi ms-based high-throughput screening method for substances inhibiting aggregation of alzheimer's amyloid beta peptides
WO2009076158A1 (en) * 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
JP6088123B2 (ja) 2008-02-01 2017-03-01 アルファ−オー・ペプチドズ・アーゲーAlpha−O Peptides Ag ワクチンとして有用な自己会合ペプチドナノ粒子
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
JP2011525477A (ja) 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド 免疫調節剤粒子および処置方法
US20090297621A1 (en) 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
HUE047004T2 (hu) 2008-06-16 2020-04-28 Pfizer Hatóanyaggal töltött polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010003009A2 (en) * 2008-07-01 2010-01-07 Emory University Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
JP5667566B2 (ja) 2008-08-06 2015-02-12 ノバルティス アーゲー 免疫原性組成物における使用のための微粒子
EP2324025A1 (en) 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
ES2433371T3 (es) 2008-08-11 2013-12-10 Glaxosmithkline Llc Derivados de purina para uso en el tratamiento de enfermedades alérgicas, inflamatorias e infecciosas
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CA2756996C (en) 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof
WO2010123569A2 (en) 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
US9797000B2 (en) 2009-05-01 2017-10-24 Qiagen Gaithersburg Inc. Non-target amplification method for detection of RNA splice-forms in a sample
AU2010254549B2 (en) * 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EP3058953A1 (en) 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
MX343908B (es) 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US20110171248A1 (en) 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
US20110272836A1 (en) 2010-04-12 2011-11-10 Selecta Biosciences, Inc. Eccentric vessels
CN105194665A (zh) 2010-05-26 2015-12-30 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
AU2011291522A1 (en) 2010-08-20 2013-01-24 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E
MX2013002173A (es) * 2010-08-23 2013-05-06 Selecta Biosciences Inc Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos.
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
EP2694040A4 (en) 2011-03-25 2014-09-03 Selecta Biosciences Inc SYNTHETIC NANOTRACKERS WITH OSMOTICALLY MEDIATED RELEASE
CN118078979A (zh) 2011-04-29 2024-05-28 西莱克塔生物科技公司 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013036302A1 (en) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells
US10434088B2 (en) 2013-05-03 2019-10-08 Selecta Biosciences, Inc. Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
DK3003306T3 (da) 2013-06-04 2020-11-30 Selecta Biosciences Inc Gentagen indgivelse af ikke-immunosupressive antigenspecifikke immunterapeutika
US20160220501A1 (en) 2015-02-03 2016-08-04 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
US20150359865A1 (en) 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
EA201692512A1 (ru) 2014-06-25 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
WO2016037165A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
HUE054894T2 (hu) 2014-11-05 2021-10-28 Selecta Biosciences Inc Rapamicint stabil, túltelített állapotban tartalmazó szintetikus nanohordozókkal kapcsolatos módszerek és készítmények

Similar Documents

Publication Publication Date Title
JP2012528155A5 (cg-RX-API-DMAC7.html)
JP2016094411A5 (cg-RX-API-DMAC7.html)
Wu et al. Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer
Ma et al. Nanoparticles of poly (lactide-co-glycolide)-da-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment
Singh et al. Recent biomedical applications and patents on biodegradable polymer-PLGA
Seow et al. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles
ES2584840T3 (es) Compuesto de un derivado de resorcinol con un polímero
Li et al. Alternating block polyurethanes based on PCL and PEG as potential nerve regeneration materials
ES2462090T3 (es) Nanopartículas poliméricas cargadas de fármaco y métodos para preparar y usar las mismas
JP2010513526A5 (cg-RX-API-DMAC7.html)
JP2012012418A5 (cg-RX-API-DMAC7.html)
JP2009532087A5 (cg-RX-API-DMAC7.html)
JP5709113B2 (ja) 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム
JP2010534513A5 (cg-RX-API-DMAC7.html)
JP2017511322A5 (cg-RX-API-DMAC7.html)
JP2012509264A5 (cg-RX-API-DMAC7.html)
JPWO2007111211A1 (ja) タキサン類の高分子結合体
JP2015107945A5 (cg-RX-API-DMAC7.html)
Yao et al. Biodegradable pH-sensitive polyurethane micelles with different polyethylene glycol (PEG) locations for anti-cancer drug carrier applications
TW201030035A (en) Novel amphiphilic copolymers and fabrication method thereof
CN106177979B (zh) 一种具有多药协同作用的抗肿瘤高分子键合药及其制备方法
JP6590995B2 (ja) カンプトテシン類高分子誘導体の医薬製剤
ES2523431T3 (es) Solubilización y suministro dirigido de fármacos con polímeros anfifílicos de autoensamblaje
Zhou et al. Acetal-linked polymeric prodrug micelles based on aliphatic polycarbonates for paclitaxel delivery: Preparation, characterization, in vitro release and anti-proliferation effects
NZ611145A (en) Peg or peg block copolymers for treating colorectal cancer